|Hormone therapy with or without docetaxel and estramustine in treating patients with prostate cancer that is locally advanced or at high risk of relapse|
Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse (patient version).
We assessed this page using an appraisal instrument developed by Minervation specifically for this project. This approach is still in development, so you should regard the assessments as a general guide. Click here to find out more, or to let us know how you think the approach could be improved.
National Cancer Institute (NCI)